FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300690014> ?p ?o ?g. }

• W4300690014 endingPage "2442" @default.
• W4300690014 startingPage "2435" @default.
• W4300690014 abstract "Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo. The Abaloparatide for the Treatment of Men with Osteoporosis (ATOM; NCT03512262) study evaluated the efficacy and safety of abaloparatide compared with placebo in men. Eligible men aged 40 to 85 years with osteoporosis were randomized 2:1 to daily subcutaneous injections of abaloparatide 80 μg or placebo for 12 months. The primary endpoint was change from baseline in lumbar spine BMD. Key secondary endpoints included BMD change from baseline at the total hip and femoral neck. A total of 228 men were randomized (abaloparatide, n = 149; placebo, n = 79). Baseline characteristics were similar across treatment groups (mean age, 68.3 years; mean lumbar spine BMD T-score, -2.1). At 12 months, BMD gains were greater with abaloparatide compared with placebo at the lumbar spine (least squares mean percentage change [standard error]: 8.48 [0.54] versus 1.17 [0.72]), total hip (2.14 [0.27] versus 0.01 [0.35]), and femoral neck (2.98 [0.34] versus 0.15 [0.45]) (all p < 0.0001). The most common (≥5%) treatment-emergent adverse events were injection site reaction, dizziness, nasopharyngitis, arthralgia, bronchitis, hypertension, and headache. During 12 months of abaloparatide treatment, men with osteoporosis exhibited rapid and significant improvements in BMD with a safety profile consistent with previous studies. These results suggest abaloparatide can be considered as an effective anabolic treatment option for men with osteoporosis. © 2022 Radius Health Inc and The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)." @default.
• W4300690014 created "2022-10-04" @default.
• W4300690014 creator A5005289841 @default.
• W4300690014 creator A5011366503 @default.
• W4300690014 creator A5011375575 @default.
• W4300690014 creator A5033439551 @default.
• W4300690014 creator A5037555787 @default.
• W4300690014 creator A5046382845 @default.
• W4300690014 creator A5048607129 @default.
• W4300690014 creator A5053948090 @default.
• W4300690014 creator A5062747501 @default.
• W4300690014 creator A5068791484 @default.
• W4300690014 creator A5070407771 @default.
• W4300690014 creator A5072880232 @default.
• W4300690014 creator A5075226333 @default.
• W4300690014 creator A5075505037 @default.
• W4300690014 creator A5076109254 @default.
• W4300690014 creator A5080963878 @default.
• W4300690014 date "2022-10-18" @default.
• W4300690014 modified "2023-10-17" @default.
• W4300690014 title "The Efficacy and Safety of <scp>Abaloparatide‐SC</scp> in Men With Osteoporosis: A Randomized Clinical Trial" @default.
• W4300690014 cites W1511797896 @default.
• W4300690014 cites W1992053982 @default.
• W4300690014 cites W2013724724 @default.
• W4300690014 cites W2033256768 @default.
• W4300690014 cites W2044178924 @default.
• W4300690014 cites W2045608566 @default.
• W4300690014 cites W2066542463 @default.
• W4300690014 cites W2069234189 @default.
• W4300690014 cites W2073752847 @default.
• W4300690014 cites W2075195284 @default.
• W4300690014 cites W2093809946 @default.
• W4300690014 cites W2110396808 @default.
• W4300690014 cites W2123816368 @default.
• W4300690014 cites W2135241080 @default.
• W4300690014 cites W2171709369 @default.
• W4300690014 cites W2335178464 @default.
• W4300690014 cites W2417995089 @default.
• W4300690014 cites W2516614130 @default.
• W4300690014 cites W2804652579 @default.
• W4300690014 cites W2808994945 @default.
• W4300690014 cites W2810327208 @default.
• W4300690014 cites W3164851585 @default.
• W4300690014 cites W3198405278 @default.
• W4300690014 cites W4211141844 @default.
• W4300690014 cites W4226536996 @default.
• W4300690014 doi "https://doi.org/10.1002/jbmr.4719" @default.
• W4300690014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36190391" @default.
• W4300690014 hasPublicationYear "2022" @default.
• W4300690014 type Work @default.
• W4300690014 citedByCount "4" @default.
• W4300690014 countsByYear W43006900142023 @default.
• W4300690014 crossrefType "journal-article" @default.
• W4300690014 hasAuthorship W4300690014A5005289841 @default.
• W4300690014 hasAuthorship W4300690014A5011366503 @default.
• W4300690014 hasAuthorship W4300690014A5011375575 @default.
• W4300690014 hasAuthorship W4300690014A5033439551 @default.
• W4300690014 hasAuthorship W4300690014A5037555787 @default.
• W4300690014 hasAuthorship W4300690014A5046382845 @default.
• W4300690014 hasAuthorship W4300690014A5048607129 @default.
• W4300690014 hasAuthorship W4300690014A5053948090 @default.
• W4300690014 hasAuthorship W4300690014A5062747501 @default.
• W4300690014 hasAuthorship W4300690014A5068791484 @default.
• W4300690014 hasAuthorship W4300690014A5070407771 @default.
• W4300690014 hasAuthorship W4300690014A5072880232 @default.
• W4300690014 hasAuthorship W4300690014A5075226333 @default.
• W4300690014 hasAuthorship W4300690014A5075505037 @default.
• W4300690014 hasAuthorship W4300690014A5076109254 @default.
• W4300690014 hasAuthorship W4300690014A5080963878 @default.
• W4300690014 hasBestOaLocation W43006900141 @default.
• W4300690014 hasConcept C126322002 @default.
• W4300690014 hasConcept C126894567 @default.
• W4300690014 hasConcept C141071460 @default.
• W4300690014 hasConcept C142724271 @default.
• W4300690014 hasConcept C168563851 @default.
• W4300690014 hasConcept C197934379 @default.
• W4300690014 hasConcept C203092338 @default.
• W4300690014 hasConcept C204787440 @default.
• W4300690014 hasConcept C27081682 @default.
• W4300690014 hasConcept C2775854910 @default.
• W4300690014 hasConcept C2776541429 @default.
• W4300690014 hasConcept C2776886416 @default.
• W4300690014 hasConcept C71924100 @default.
• W4300690014 hasConceptScore W4300690014C126322002 @default.
• W4300690014 hasConceptScore W4300690014C126894567 @default.
• W4300690014 hasConceptScore W4300690014C141071460 @default.
• W4300690014 hasConceptScore W4300690014C142724271 @default.
• W4300690014 hasConceptScore W4300690014C168563851 @default.
• W4300690014 hasConceptScore W4300690014C197934379 @default.
• W4300690014 hasConceptScore W4300690014C203092338 @default.
• W4300690014 hasConceptScore W4300690014C204787440 @default.
• W4300690014 hasConceptScore W4300690014C27081682 @default.
• W4300690014 hasConceptScore W4300690014C2775854910 @default.
• W4300690014 hasConceptScore W4300690014C2776541429 @default.
• W4300690014 hasConceptScore W4300690014C2776886416 @default.
• W4300690014 hasConceptScore W4300690014C71924100 @default.
• W4300690014 hasFunder F4320316098 @default.
• W4300690014 hasIssue "12" @default.

• next